Empowered Funds LLC Acquires 64,150 Shares of Boston Scientific Corporation $BSX

Key Points

• Empowered Funds LLC increased its stake in Boston Scientific Corporation by 241.0%, holding 90,765 shares valued at approximately $9.16 million after acquiring an additional 64,150 shares in the first quarter.
• Boston Scientific reported earnings of $0.75 per share and revenue of $5.06 billion for the last quarter, exceeding analysts' expectations.
• Analysts have a consensus rating of "Buy" for Boston Scientific, with target prices ranging from $115.00 to $125.00, indicating strong growth prospects.

Empowered Funds LLC increased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 241.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 90,765 shares of the medical equipment provider's stock after acquiring an additional 64,150 shares during the quarter. Empowered Funds LLC's holdings in Boston Scientific were worth $9,156,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in BSX. Brighton Jones LLC lifted its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the period. Bank Pictet & Cie Europe AG lifted its stake in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after buying an additional 21,173 shares during the period. Highview Capital Management LLC DE lifted its stake in Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock valued at $2,189,000 after buying an additional 1,439 shares during the period. Algert Global LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $297,000. Finally, Gotham Asset Management LLC increased its holdings in shares of Boston Scientific by 43.7% during the fourth quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider's stock valued at $1,021,000 after acquiring an additional 3,475 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on BSX. Leerink Partners began coverage on Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Barclays upped their price target on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Truist Financial upped their price target on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Stock Performance

Shares of NYSE BSX traded down $1.11 during trading on Monday, reaching $101.60. 2,568,970 shares of the stock traded hands, compared to its average volume of 7,461,097. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a 50-day moving average of $104.86 and a 200-day moving average of $102.27. The stock has a market capitalization of $150.55 billion, a P/E ratio of 60.48, a price-to-earnings-growth ratio of 2.47 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock worth $18,397,457. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.